CMS Extends Medicare GLP-1 Bridge Through 2027 as Main Program Stalls

Key Takeaways:

• CMS extended the Medicare GLP-1 Bridge program through December 31, 2027, providing 18 months of coverage instead of the original 6-month plan
• The permanent BALANCE model for Medicare Part D faces uncertainty due to insufficient insurer participation
• Eligible Medicare beneficiaries can access Wegovy, Zepbound, and Foundayo for a $50 monthly copay starting July 1, 2026

What Just Happened

The Centers for Medicare & Medicaid Services (CMS) announced that the Medicare GLP-1 Bridge program, originally scheduled to run from July to December 2026, will now extend through December 31, 2027. This 18-month extension represents a significant shift from the temporary six-month program CMS initially planned.

Under the Bridge program, eligible Medicare beneficiaries can access GLP-1 medications for obesity treatment with a $50 monthly copay, with coverage including all formulations of Wegovy, Foundayo, and the KwikPen formulation of Zepbound.

The extension comes as the permanent BALANCE model faces implementation challenges, with CMS requiring at least 80% participation from Part D plan sponsors for the model to launch in Medicare in January 2027.

Why This Extension Matters for Medicare Coverage

This decision signals that Medicare's long-term approach to GLP-1 coverage remains unsettled. The reluctance of major Part D plan sponsors to participate in the BALANCE model may stem from concerns about costs, even with manufacturers agreeing to a $245 net price — a substantial discount from prevailing list prices.

Plans would face financial risk if their actual costs for covering GLP-1s exceeded expectations, and higher costs would translate to increased federal spending and higher Part D premiums for all enrollees.

The Bridge program operates differently than typical Medicare coverage. It runs completely separate from Part D coverage, meaning Part D sponsors bear no financial risk and don't need to opt in for their members to gain access.

For context, Medicare is prohibited by law from covering medications specifically for weight loss, while only 13 states currently cover GLP-1 drugs in their Medicaid programs as of January 2026 Source.

How the Bridge Program Works

CMS is using Humana as the central processor for the Medicare GLP-1 Bridge, leveraging the infrastructure from the Limited Income Newly Eligible Transition (LI NET) program to provide national scale for broad access starting July 1, 2026.

To access medications through the Bridge, eligible beneficiaries must have their medical provider submit a prior authorization request, and they must meet specific eligibility criteria while paying the $50 monthly copay.

Importantly, the Bridge program serves as the primary payer and won't coordinate with other insurance or accept manufacturer coupons and discount programs.

The eligibility requirements include having a BMI of 30 or higher (or 27 with weight-related health conditions) and meeting other clinical criteria that your healthcare provider will evaluate during the prior authorization process.

Financial Impact and Long-Term Concerns

The extension reveals the complexity of integrating expensive obesity medications into Medicare. While CMS hasn't disclosed the projected cost of the Bridge program, covering obesity drugs under Part D has been estimated at $25-35 billion over 10 years Source.

Implementation of the BALANCE model in Medicare faces an uncertain future, with CMS potentially needing to revise financial incentives to make participation more appealing to Part D plan sponsors.

The current list prices for these medications range from $800 to $1,200 per month, making the $50 copay a significant savings for Medicare beneficiaries. However, the long-term sustainability of such generous coverage remains a question mark as CMS works through the financial mechanics.

This pricing uncertainty has created a complex landscape where understanding your options becomes crucial for making informed decisions about treatment.

What This Means for You

If you're on Medicare and considering GLP-1 treatment for weight loss, this extension provides crucial certainty. You now have guaranteed access to obesity drug coverage at a $50 copay for 18 months instead of the original six-month window.

However, you'll need to meet specific clinical criteria and work with your provider to navigate the prior authorization process. The program covers major GLP-1 medications, but you should verify which specific formulations qualify when discussing your medication options with your healthcare team.

For those already planning treatment, this extension eliminates the uncertainty about what happens after December 2026. You can now plan for consistent access through the end of 2027 while the broader Medicare coverage questions get resolved.

The prior authorization process requires your healthcare provider to document your medical history, previous weight loss attempts, and current health conditions. Having this information ready can help streamline your application.

To explore your options and understand the eligibility requirements, you can find a clinic near you that can help with the prior authorization process and guide you through the Bridge program requirements.

Looking Ahead: What Happens After 2027

The extended timeline gives CMS more opportunity to work out the kinks in the permanent BALANCE model or develop alternative solutions for long-term GLP-1 coverage under Medicare.

The success or failure of the Bridge program will likely influence future policy decisions about obesity medication coverage. CMS will be closely monitoring utilization rates, health outcomes, and overall program costs during this extended period.

For Medicare beneficiaries, this extension provides breathing room to start treatment without worrying about immediate coverage gaps. However, it's worth staying informed about developments in the permanent coverage model as 2027 approaches.

The broader trend toward recognizing obesity as a medical condition requiring treatment continues to gain momentum, with this Bridge program representing a significant step forward in Medicare policy, even as a temporary measure.